Research ExplorerPublicationsNeurofibromin specific antibody differentiates malignant per...

Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms

Standard

Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. / Reuss, David E; Habel, Antje; Hagenlocher, Christian; Mucha, Jana; Ackermann, Ulrike; Tessmer, Claudia; Meyer, Jochen; Capper, David; Moldenhauer, Gerhard; Mautner, Viktor-Felix; Frappart, Pierre-Olivier; Schittenhelm, Jens; Hartmann, Christian; Hagel, Christian; Katenkamp, Kathrin; Petersen, Iver; Mechtersheimer, Gunhild; von Deimling, Andreas.

In: ACTA NEUROPATHOL, Vol. 127, No. 4, 01.04.2014, p. 565-72.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Reuss, DE, Habel, A, Hagenlocher, C, Mucha, J, Ackermann, U, Tessmer, C, Meyer, J, Capper, D, Moldenhauer, G, Mautner, V-F, Frappart, P-O, Schittenhelm, J, Hartmann, C, Hagel, C, Katenkamp, K, Petersen, I, Mechtersheimer, G & von Deimling, A 2014, 'Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms', ACTA NEUROPATHOL, vol. 127, no. 4, pp. 565-72. https://doi.org/10.1007/s00401-014-1246-6

APA

Reuss, D. E., Habel, A., Hagenlocher, C., Mucha, J., Ackermann, U., Tessmer, C., Meyer, J., Capper, D., Moldenhauer, G., Mautner, V-F., Frappart, P-O., Schittenhelm, J., Hartmann, C., Hagel, C., Katenkamp, K., Petersen, I., Mechtersheimer, G., & von Deimling, A. (2014). Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. ACTA NEUROPATHOL, 127(4), 565-72. https://doi.org/10.1007/s00401-014-1246-6

Vancouver

Reuss DE, Habel A, Hagenlocher C, Mucha J, Ackermann U, Tessmer C et al. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. ACTA NEUROPATHOL. 2014 Apr 1;127(4):565-72. https://doi.org/10.1007/s00401-014-1246-6

Bibtex

@article{e0dc154e24784dc2b66d0ad940e9ede0,
title = "Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms",
abstract = "Malignant peripheral nerve sheath tumors (MPNST) derive from the Schwann cell or perineurial cell lineage and occur either sporadically or in association with the tumor syndrome neurofibromatosis type 1 (NF1). MPNST often pose a diagnostic challenge due to their frequent lack of pathognomonic morphological or immunohistochemical features. Mutations in the NF1 tumor suppressor gene are found in all NF1-associated and many sporadic MPNST. The presence of NF1 mutation may have the potential to differentiate MPNST from several morphologically similar neoplasms; however, mutation detection is hampered by the size of the gene and the lack of mutational hot spots. Here we describe a newly developed monoclonal antibody binding to the C-terminus of neurofibromin (clone NFC) which was selected for optimal performance in routinely processed formalin-fixed and paraffin-embedded tissue. NFC immunohistochemistry revealed loss of neurofibromin in 22/25 (88 %) of NF1-associated and 26/61 (43 %) of sporadic MPNST. There was a strong association of neurofibromin loss with deletions affecting the NF1 gene (P < 0.01). In a series of 256 soft tissue tumors of different histotypes NFC staining showed loss of neurofibromin in 2/8 myxofibrosarcomas, 2/12 (16 %) pleomorphic liposarcomas, 1/16 (6 %) leiomyosarcomas, and 4/28 (14 %) unclassified undifferentiated pleomorphic sarcomas. However, loss of neurofibromin was not observed in 22 synovial sarcomas, 27 schwannomas, 23 solitary fibrous tumors, 14 low-grade fibromyxoid sarcomas, 50 dedifferentiated liposarcomas, 27 myxoid liposarcomas, 13 angiosarcomas, 9 extraskeletal myxoid chondrosarcomas, and 7 epitheloid sarcomas. Immunohistochemistry using antibody NFC may substantially facilitate sarcoma research and diagnostics.",
author = "Reuss, {David E} and Antje Habel and Christian Hagenlocher and Jana Mucha and Ulrike Ackermann and Claudia Tessmer and Jochen Meyer and David Capper and Gerhard Moldenhauer and Viktor-Felix Mautner and Pierre-Olivier Frappart and Jens Schittenhelm and Christian Hartmann and Christian Hagel and Kathrin Katenkamp and Iver Petersen and Gunhild Mechtersheimer and {von Deimling}, Andreas",
year = "2014",
month = apr,
day = "1",
doi = "10.1007/s00401-014-1246-6",
language = "English",
volume = "127",
pages = "565--72",
journal = "ACTA NEUROPATHOL",
issn = "0001-6322",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms

AU - Reuss, David E

AU - Habel, Antje

AU - Hagenlocher, Christian

AU - Mucha, Jana

AU - Ackermann, Ulrike

AU - Tessmer, Claudia

AU - Meyer, Jochen

AU - Capper, David

AU - Moldenhauer, Gerhard

AU - Mautner, Viktor-Felix

AU - Frappart, Pierre-Olivier

AU - Schittenhelm, Jens

AU - Hartmann, Christian

AU - Hagel, Christian

AU - Katenkamp, Kathrin

AU - Petersen, Iver

AU - Mechtersheimer, Gunhild

AU - von Deimling, Andreas

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Malignant peripheral nerve sheath tumors (MPNST) derive from the Schwann cell or perineurial cell lineage and occur either sporadically or in association with the tumor syndrome neurofibromatosis type 1 (NF1). MPNST often pose a diagnostic challenge due to their frequent lack of pathognomonic morphological or immunohistochemical features. Mutations in the NF1 tumor suppressor gene are found in all NF1-associated and many sporadic MPNST. The presence of NF1 mutation may have the potential to differentiate MPNST from several morphologically similar neoplasms; however, mutation detection is hampered by the size of the gene and the lack of mutational hot spots. Here we describe a newly developed monoclonal antibody binding to the C-terminus of neurofibromin (clone NFC) which was selected for optimal performance in routinely processed formalin-fixed and paraffin-embedded tissue. NFC immunohistochemistry revealed loss of neurofibromin in 22/25 (88 %) of NF1-associated and 26/61 (43 %) of sporadic MPNST. There was a strong association of neurofibromin loss with deletions affecting the NF1 gene (P < 0.01). In a series of 256 soft tissue tumors of different histotypes NFC staining showed loss of neurofibromin in 2/8 myxofibrosarcomas, 2/12 (16 %) pleomorphic liposarcomas, 1/16 (6 %) leiomyosarcomas, and 4/28 (14 %) unclassified undifferentiated pleomorphic sarcomas. However, loss of neurofibromin was not observed in 22 synovial sarcomas, 27 schwannomas, 23 solitary fibrous tumors, 14 low-grade fibromyxoid sarcomas, 50 dedifferentiated liposarcomas, 27 myxoid liposarcomas, 13 angiosarcomas, 9 extraskeletal myxoid chondrosarcomas, and 7 epitheloid sarcomas. Immunohistochemistry using antibody NFC may substantially facilitate sarcoma research and diagnostics.

AB - Malignant peripheral nerve sheath tumors (MPNST) derive from the Schwann cell or perineurial cell lineage and occur either sporadically or in association with the tumor syndrome neurofibromatosis type 1 (NF1). MPNST often pose a diagnostic challenge due to their frequent lack of pathognomonic morphological or immunohistochemical features. Mutations in the NF1 tumor suppressor gene are found in all NF1-associated and many sporadic MPNST. The presence of NF1 mutation may have the potential to differentiate MPNST from several morphologically similar neoplasms; however, mutation detection is hampered by the size of the gene and the lack of mutational hot spots. Here we describe a newly developed monoclonal antibody binding to the C-terminus of neurofibromin (clone NFC) which was selected for optimal performance in routinely processed formalin-fixed and paraffin-embedded tissue. NFC immunohistochemistry revealed loss of neurofibromin in 22/25 (88 %) of NF1-associated and 26/61 (43 %) of sporadic MPNST. There was a strong association of neurofibromin loss with deletions affecting the NF1 gene (P < 0.01). In a series of 256 soft tissue tumors of different histotypes NFC staining showed loss of neurofibromin in 2/8 myxofibrosarcomas, 2/12 (16 %) pleomorphic liposarcomas, 1/16 (6 %) leiomyosarcomas, and 4/28 (14 %) unclassified undifferentiated pleomorphic sarcomas. However, loss of neurofibromin was not observed in 22 synovial sarcomas, 27 schwannomas, 23 solitary fibrous tumors, 14 low-grade fibromyxoid sarcomas, 50 dedifferentiated liposarcomas, 27 myxoid liposarcomas, 13 angiosarcomas, 9 extraskeletal myxoid chondrosarcomas, and 7 epitheloid sarcomas. Immunohistochemistry using antibody NFC may substantially facilitate sarcoma research and diagnostics.

U2 - 10.1007/s00401-014-1246-6

DO - 10.1007/s00401-014-1246-6

M3 - SCORING: Journal article

C2 - 24464231

VL - 127

SP - 565

EP - 572

JO - ACTA NEUROPATHOL

JF - ACTA NEUROPATHOL

SN - 0001-6322

IS - 4

ER -